Survival After Pancreatoduodenectomy

Trede, M.; Chir, B.; Hon,; Schwall, G.; Saeger, Hans‐Detlev

doi:10.1097/00000658-199004000-00011

Cited by 1,026 publications

(218 citation statements)

References 22 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…Although there is some evidence that early diagnosis and resection can result in improved long-term survival (51), there is a paucity of specific molecular markers to detect pancreatic adenocarcinoma or to identify patients at higher risk for cancer development (39,40). Further study of the differential expression of CCK receptors may reveal CCK-A receptors as a useful biomarker for pancreatic adenocarcinoma diagnosis and management.…”

Section: Discussionmentioning

confidence: 99%

Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Weinberg

Ruggeri²,

Barber³

et al. 1997

J. Clin. Invest.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Weinberg

Ruggeri²,

Barber³

et al. 1997

J. Clin. Invest.

View full text Add to dashboard Cite

“…In recent series, resection for cure has been possible in 15 to 20% of unselected patients21 and in 29 to 34% of patients screened as suitable candidates for curative resection.7.S Representative recent studies have reported 5 year survival rates for pancreatic cancer of 6.8%, 9%, 17%, and 25%. [9][10][11][12] In tumors other than ductal adenocarcinoma, 5 year survival is higher-for example, 9% versus 36% in Wade and coworkers' study.to Mortality after Whipple pancreaticoduodenectomy resection has decreased. Several decades ago mortality ranged from 15 to 25%.1 More recently, mortality rates varying from 012.13 to 8%1.10 have been reported.…”

mentioning

confidence: 99%

Color flow sonography in evaluating the resectability of periampullary and pancreatic tumors

Ralls

Wren

Radin

et al. 1997

Journal of Ultrasound in Medicine

View full text Add to dashboard Cite

Over the past several years, we have develo~ a teclmique to assess the resectability of periampullary and pancreatic tumors using color flow sonography. This is a feasibility study to determine if sonography with color flow imaging can play a role in evaluating patients with periampullary and pancreatic tumors. This study comprises a retrospective analysis of 51 patients referred for color flow sonographic evaluation of resectability of periampullary and pancreatic neoplasm. Scanning was performed with state-of· the-art color flow sonographic systems. Vessels that were touched or occluded by tumor were categorized according to a Pancreatic Color Doppler Score. Other factors affecting resectability (metastasis, enlarged nodes) were recorded. Sonographic findings were correlated with surgical resectability and pathologic findings regarding tumor margins. The color flow study was complete teclmically (all index vessels visualized) in 49 of 51 patients (96%). In all, 643 of 647 vessels (99.4%) were imaged. Forty-five patients had sufficient surgical, pathologic, or clinical proof to be included in the resectability analysis. All 18 patients with circumferential tumor or vascular occlusion (Pancreatic Color Doppler Score 4 and 5) were found to have unresectable disease. All 10 )'atients in whom tumor did not touch (Pancreatic Color Doppler Score 0) had negative margins. All 30 patients considered to have unresectable tumors sonographically could not be resected. Patients in this category had one or more of the following: positive pathologic margins, positive nodes, liver metastasis, or not clinically resectable. Six of 15 considered resectable sonographically (40%) were unresectable for cure. Surgeons believed that color flow sonography influenced management in 10 of 45 patients (22% overall). Color flow sonography, a painless, noninvasive, and relatively inexpensive examination, may be an effective screening tool to evaluate periampullary and pancreatic neoplasms for resectability. Our data show that color flow sonography can correctly predict unresectability of periampullary and pancreatic neoplasms. Any future evaluation of imaging and management of periampullary and pancreatic tumors should include color flow sonography. KEY WORDS: Ultrasonography, Doppler studies; Pancreas, tumors; Tumors, periampullary; Tumors, pancreatic.T he prognosis for pancreatic carcinoma and other pancreatic neoplasms is grim. The estimated overall cure rate for pancreatic ductal adenocarcinoma is less than 1%.1 The only hope for cure remains surgical resection. In the last decade, surgical results have improved and operative morbidity and mortality have decreased. In recent series, resection for cure has been possible in 15 to 20% of unselected patients21 and in 29 to 34% of patients screened as suitable candidates for

show abstract

“…[28][29][30] We analyzed the correlations between clinicopathological indices and immunohistochemical staining for surgical specimens curatively resected from primary pancreatic adenocarcinoma using several monoclonal antibodies: anti-CD44s, anti-CD44v6 (exon 11) antibody and a recently developed anti-CD44v2 (exon 7) antibody whose specificity for the CD44v2 epitope has been confirmed by Borgya et al 31) …”

mentioning

confidence: 99%

Expression of CD44 Variants and Its Association with Survival in Pancreatic Cancer

Gotoda

Matsumura

Kondo

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope. The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) Key words: CD44 variants -Pancreatic cancer -Metastasis -Prognosis -Immunohistochemistry CD44 is a heavily glycosylated cell surface molecule which is involved in cell-cell and cell-matrix interactions 1, 2) and mediates several functions, such as extracellular matrix cell adhesion, 3, 4) lymphocyte homing, 5,6) T cell activation 7) and tumor metastasis. 7,8) The CD44 family of polymorphic transmembrane glycoproteins is encoded by a complex gene 7,[9][10][11][12] that occupies a stretch of 60-80 kD assigned to the human chromosomal locus 11p13. Its human form is composed of at least 21 exons, 10 of which are constitutively expressed on almost all cell types to produce a heavily glycosylated 85-90 kD isoform known as standard form CD44s (Fig. 1). The remaining exons can be alternatively spliced in various combinations, and their products are incorporated into the polypeptide backbone encoded by the standard form exons. This results in a large array of protein isoforms (CD44v) which are differentially expressed in various tissues and at various stages in development. 13)Recently, it was demonstrated that the expression of one variant isoform of CD44 distinguished metastatic from non-metastatic pancreatic carcinoma cell lines in the rat.8) Evidence that CD44v itself has a role in metastasis came from the demonstration that transfection with cDNA encoding this isoform converted non-metastatic carcinoma rat cells into metastatic cells. 8) Although the functions of CD44v isoforms in humans remain unclear, it is thought that CD44v isoforms play an important role in the growth and metastasis of several kinds of tumors. [14][15][16][17][18] It has been demonstrated that the disturbed activity of the CD44 gene in malignant tumors results in the accumulation of immature mRNA transcripts containing introns 10,19) from the CD44 gene. Moreover, in a recent study, 20) direct comparison of Southern blots with western blots from matched tumor cell line extracts indicated that most of the diverse mRNA isoforms are not detectably translated into proteins. These findings, together with data from reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis, show that the overexpression at the protein level involves only a minority of aberrant RNA transcripts.Recent clinic...

show abstract

Survival After Pancreatoduodenectomy

Cited by 1,026 publications

References 22 publications

Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Color flow sonography in evaluating the resectability of periampullary and pancreatic tumors

Expression of CD44 Variants and Its Association with Survival in Pancreatic Cancer

Contact Info

Product

Resources

About